Dear Editor, With great interest we read the paper by Salimian et al. [1], describing the distribution of different v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in lung adenocarcinomas (ADCs), which has recently been published in Acta Cytologica. Their series was entirely composed of BRAF mutant cases, in order to investigate the relative prevalence of BRAF p.V600E versus BRAF non-p.V600E mutations. This issue is of great clinical relevance, since only BRAF p.V600E can be targeted by dedicated treatment [2]. This study showed that p.V600E occurred in 10 (28%) of all 36 cases and it was more common in females
BRAF mutations in lung cancer / Pisapia, P.; Pepe, F.; Malapelle, U.; Troncone, G.. - In: ACTA CYTOLOGICA. - ISSN 0001-5547. - 63:3(2019), pp. 247-250. [10.1159/000496478]
BRAF mutations in lung cancer
Pisapia P.Membro del Collaboration Group
;Malapelle U.Membro del Collaboration Group
;
2019
Abstract
Dear Editor, With great interest we read the paper by Salimian et al. [1], describing the distribution of different v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations in lung adenocarcinomas (ADCs), which has recently been published in Acta Cytologica. Their series was entirely composed of BRAF mutant cases, in order to investigate the relative prevalence of BRAF p.V600E versus BRAF non-p.V600E mutations. This issue is of great clinical relevance, since only BRAF p.V600E can be targeted by dedicated treatment [2]. This study showed that p.V600E occurred in 10 (28%) of all 36 cases and it was more common in femalesI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
